Achieve Life Sciences (NASDAQ:ACHV) CFO Sells $146,175.20 in Stock

Key Points

• Achieve Life Sciences' CFO, Mark Oki, sold 50,060 shares for $146,175.20, representing a 28.12% decrease in his ownership, leaving him with 127,940 shares valued at approximately $373,584.80.
• The company reported a quarterly EPS of ($0.37), matching analysts' consensus estimates, while expecting -1.17 EPS for the current fiscal year.
• Wall Street analysts have given Achieve Life Sciences a consensus rating of "Strong Buy", with a target price averaging $14.67, significantly higher than its current trading price of $2.95.

Achieve Life Sciences, Inc. (NASDAQ:ACHV - Get Free Report) CFO Mark K. Oki sold 50,060 shares of the company's stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $2.92, for a total value of $146,175.20. Following the transaction, the chief financial officer directly owned 127,940 shares of the company's stock, valued at $373,584.80. The trade was a 28.12% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Achieve Life Sciences Stock Up 4.9%

Shares of NASDAQ:ACHV traded up $0.14 during trading on Tuesday, hitting $3.09. The stock had a trading volume of 758,438 shares, compared to its average volume of 648,847. Achieve Life Sciences, Inc. has a 12 month low of $1.84 and a 12 month high of $5.31. The company has a market capitalization of $158.10 million, a PE ratio of -2.12 and a beta of 1.53. The firm's fifty day moving average is $2.79 and its 200 day moving average is $2.77. The company has a quick ratio of 6.64, a current ratio of 6.64 and a debt-to-equity ratio of 0.21.

Achieve Life Sciences (NASDAQ:ACHV - Get Free Report) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.37). Analysts anticipate that Achieve Life Sciences, Inc. will post -1.17 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright initiated coverage on Achieve Life Sciences in a research report on Thursday, August 21st. They issued a "buy" rating and a $12.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating and two have assigned a Buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Strong Buy" and an average price target of $14.67.

Institutional Trading of Achieve Life Sciences

Several hedge funds and other institutional investors have recently made changes to their positions in ACHV. Northern Trust Corp grew its stake in shares of Achieve Life Sciences by 11.7% in the 4th quarter. Northern Trust Corp now owns 416,796 shares of the biopharmaceutical company's stock worth $1,467,000 after buying an additional 43,682 shares during the last quarter. Bank of America Corp DE grew its stake in shares of Achieve Life Sciences by 37.0% in the 4th quarter. Bank of America Corp DE now owns 36,168 shares of the biopharmaceutical company's stock worth $127,000 after buying an additional 9,760 shares during the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Achieve Life Sciences in the 4th quarter worth approximately $62,000. XTX Topco Ltd purchased a new stake in shares of Achieve Life Sciences in the 1st quarter worth approximately $99,000. Finally, Invesco Ltd. grew its stake in shares of Achieve Life Sciences by 338.7% in the 1st quarter. Invesco Ltd. now owns 73,644 shares of the biopharmaceutical company's stock worth $197,000 after buying an additional 56,856 shares during the last quarter. Hedge funds and other institutional investors own 33.52% of the company's stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.